J Clin Immunol 1986,
PMID: 2940258
Ernst, M; Kern, P; Flad, H D; Ulmer, A J
In the context of a clinical phase I/II therapy study with recombinant interleukin-2 (rIL-2), we monitored immunological alterations in four patients with acquired immune deficiency syndrome (AIDS) and three patients with AIDS-related complex (ARC). By determining the surface phenotypes and in vitro functions of peripheral blood mononuclear cells (PBMC) before, during, and after treatment with rIL-2, we observed transient changes in all important leukocyte subpopulations, a minor restoration of immune reactivity in vitro, and an improvement in skin reactivity in vivo. In particular, we found a transient increase in C3b receptor-mediated monocyte activation in ARC patients; no influence of therapy on the otherwise intact LPS-induced interleukin-1 production in vitro; in some patients a transient corrective influence on the high pretherapeutic immunoglobulin secretion of B cells and their nonresponsiveness to pokeweed mitogen; low T-cell responses to soluble antigens and alloantigens, which were partially restored during rIL-2 treatment in ARC patients and in one AIDS patient; defective NK activity in PBMC of two AIDS patients, which was found to be restored when measured at the end of rIL-2 therapy; and a rather constant phenotypic pattern of PBMC in each patient during therapy except for the decreasing proportion of OKT9-positive lymphocytes in AIDS patients, the increasing proportion of Leu8-Leu3a+ lymphocytes in all patients, and in particular, the transient significant decrease in the Leu7+/OKT3+ ratio, which pretherapeutically was very high in AIDS patients (0.78 +/- 0.21) and high in ARC patients (0.48 +/- 0.06) as compared to healthy controls (0.18 +/- 0.08).
Diseases/Pathways annotated by Medline MESH: Acquired Immunodeficiency Syndrome
Document information provided by NCBI PubMed
Text Mining Data
interleukin-1 → LPS: "
In particular, we found a transient increase in C3b receptor mediated monocyte activation in ARC patients ; no influence of therapy on the otherwise intact
LPS induced
interleukin-1 production in vitro ; in some patients a transient corrective influence on the high pretherapeutic immunoglobulin secretion of B cells and their nonresponsiveness to pokeweed mitogen ; low T-cell responses to soluble antigens and alloantigens, which were partially restored during rIL-2 treatment in ARC patients and in one AIDS patient ; defective NK activity in PBMC of two AIDS patients, which was found to be restored when measured at the end of rIL-2 therapy ; and a rather constant phenotypic pattern of PBMC in each patient during therapy except for the decreasing proportion of OKT9 positive lymphocytes in AIDS patients, the increasing proportion of Leu8-Leu3a+ lymphocytes in all patients, and in particular, the transient significant decrease in the Leu7+/OKT3+ ratio, which pretherapeutically was very high in AIDS patients ( 0.78 +/- 0.21 ) and high in ARC patients ( 0.48 +/- 0.06 ) as compared to healthy controls ( 0.18 +/- 0.08 )
"
C3b → interleukin-1: "
In particular, we found a transient increase in C3b receptor mediated monocyte activation in ARC patients ; no influence of therapy on the otherwise intact LPS induced interleukin-1 production in vitro ; in some patients a transient corrective influence on the high pretherapeutic immunoglobulin secretion of B cells and their nonresponsiveness to pokeweed mitogen ; low T-cell responses to soluble antigens and alloantigens, which were partially restored during rIL-2 treatment in ARC patients and in one AIDS patient ; defective NK activity in PBMC of two AIDS patients, which was found to be restored when measured at the end of rIL-2 therapy ; and a rather constant phenotypic pattern of PBMC in each patient during therapy except for the decreasing proportion of OKT9 positive lymphocytes in AIDS patients, the increasing proportion of Leu8-Leu3a+ lymphocytes in all patients, and in particular, the transient significant decrease in the Leu7+/OKT3+ ratio, which pretherapeutically was very high in AIDS patients ( 0.78 +/- 0.21 ) and high in ARC patients ( 0.48 +/- 0.06 ) as compared to healthy controls ( 0.18 +/- 0.08 )
"
Manually curated Databases
No curated data.